| Candice Black, DO | |
|
1 Medical Center Dr, Pathology Dept, Dhmc, Lebanon, NH 03756-1000 | |
| (603) 650-7211 | |
| Not Available |
| Full Name | Candice Black |
|---|---|
| Gender | Female |
| Speciality | Pathology |
| Experience | 28 Years |
| Location | 1 Medical Center Dr, Lebanon, New Hampshire |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528093887 | NPI | - | NPPES |
| 30222118 | Medicaid | NH | |
| 1009038 | Medicaid | VT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0101X | Pathology - Anatomic Pathology | 11684 (New Hampshire) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mary Hitchcock Memorial Hospital | Lebanon, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dartmouth-hitchcock Clinic | 4183537509 | 1139 |
News Archive
Developments in pharmaceuticals make headlines: the race to make painkillers that are difficult to abuse, state action on regulating compounding pharmacies and the difference in how much different Americans pay for prescriptions.
A Texas A&M University team of scientists and engineers is leading the development of a device that can be used to rapidly identify antibodies produced by human B cells that can neutralize infection by SARS-CoV-2, the causative agent of COVID-19.
Regulus Therapeutics Inc. announced today that it has obtained exclusive rights from the University of Wuerzburg to intellectual property covering methods for modulating microRNA-21. Regulus scientists and collaborators have shown that microRNA-21, (miR-21), is dysregulated in mouse models of cardiac disease and fibrosis, and that antagonizing miR-21 with therapeutic oligonucleotides targeting miR-21 inhibits fibrosis and attenuates cardiac function in such models. Regulus is currently developing a microRNA therapeutic targeting miR-21 as an anti-fibrotic therapy.
During a Dec. 8 press conference about Operation Warp Speed, President Donald Trump likened the spread of the coronavirus throughout the population — which experts agree bestows some immunity on the people who became ill — to having a COVID-19 vaccine.
WuXi PharmaTech, a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that its Suzhou non-clinical safety testing facility received full accreditation from the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC). As a result of an extensive on-site evaluation, AAALAC determined that WuXi PharmaTech's facility meets the highest standards of animal care and research practices.
› Verified 9 days ago
| Entity Name | Dartmouth-hitchcock Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548210198 PECOS PAC ID: 4183537509 Enrollment ID: O20040809000442 |
News Archive
Developments in pharmaceuticals make headlines: the race to make painkillers that are difficult to abuse, state action on regulating compounding pharmacies and the difference in how much different Americans pay for prescriptions.
A Texas A&M University team of scientists and engineers is leading the development of a device that can be used to rapidly identify antibodies produced by human B cells that can neutralize infection by SARS-CoV-2, the causative agent of COVID-19.
Regulus Therapeutics Inc. announced today that it has obtained exclusive rights from the University of Wuerzburg to intellectual property covering methods for modulating microRNA-21. Regulus scientists and collaborators have shown that microRNA-21, (miR-21), is dysregulated in mouse models of cardiac disease and fibrosis, and that antagonizing miR-21 with therapeutic oligonucleotides targeting miR-21 inhibits fibrosis and attenuates cardiac function in such models. Regulus is currently developing a microRNA therapeutic targeting miR-21 as an anti-fibrotic therapy.
During a Dec. 8 press conference about Operation Warp Speed, President Donald Trump likened the spread of the coronavirus throughout the population — which experts agree bestows some immunity on the people who became ill — to having a COVID-19 vaccine.
WuXi PharmaTech, a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that its Suzhou non-clinical safety testing facility received full accreditation from the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC). As a result of an extensive on-site evaluation, AAALAC determined that WuXi PharmaTech's facility meets the highest standards of animal care and research practices.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Candice Black, DO 1 Medical Center Dr, Pathology Dept, Dhmc, Lebanon, NH 03756-1000 Ph: (603) 650-7211 | Candice Black, DO 1 Medical Center Dr, Pathology Dept, Dhmc, Lebanon, NH 03756-1000 Ph: (603) 650-7211 |
News Archive
Developments in pharmaceuticals make headlines: the race to make painkillers that are difficult to abuse, state action on regulating compounding pharmacies and the difference in how much different Americans pay for prescriptions.
A Texas A&M University team of scientists and engineers is leading the development of a device that can be used to rapidly identify antibodies produced by human B cells that can neutralize infection by SARS-CoV-2, the causative agent of COVID-19.
Regulus Therapeutics Inc. announced today that it has obtained exclusive rights from the University of Wuerzburg to intellectual property covering methods for modulating microRNA-21. Regulus scientists and collaborators have shown that microRNA-21, (miR-21), is dysregulated in mouse models of cardiac disease and fibrosis, and that antagonizing miR-21 with therapeutic oligonucleotides targeting miR-21 inhibits fibrosis and attenuates cardiac function in such models. Regulus is currently developing a microRNA therapeutic targeting miR-21 as an anti-fibrotic therapy.
During a Dec. 8 press conference about Operation Warp Speed, President Donald Trump likened the spread of the coronavirus throughout the population — which experts agree bestows some immunity on the people who became ill — to having a COVID-19 vaccine.
WuXi PharmaTech, a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that its Suzhou non-clinical safety testing facility received full accreditation from the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC). As a result of an extensive on-site evaluation, AAALAC determined that WuXi PharmaTech's facility meets the highest standards of animal care and research practices.
› Verified 9 days ago
Dr. Charles Harker Rhodes Iii, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 1 Medical Center Dr, Department Of Pathology, Lebanon, NH 03756 Phone: 603-650-7744 | |
Dr. Zbigniew Macdonald Szczepiorkowski, MD, PHD Pathology Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-653-9907 Fax: 603-650-4845 | |
Dr. Melissa Louise Petras, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-5000 | |
Dr. Kim T Ornvold, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 1 Medical Center Dr, Dhmc - Dept Of Pathology, Lebanon, NH 03756 Phone: 603-650-7211 | |
Seth Charles Lummus, D.O. Pathology Medicare: Not Enrolled in Medicare Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-7211 | |
Dr. Arief Suriawinata, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Dhmc - Pathology, Lebanon, NH 03756 Phone: 603-650-7048 | |
Elena Zarovnaya, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-8458 |